A Meta-Analysis of Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor in the Treatment of Acute Myocardial Infarction
- 15 November 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 22 (1), 45-54
- https://doi.org/10.1007/s10557-007-6072-9
Abstract
This project was aimed at evaluating the safety and efficacy of granulocyte colony-stimulating factor (G-CSF) as an adjunctive therapy to the standard therapy [percutaneous coronary interventions (PCI) and conventional medication] after acute myocardial infarction (AMI). A meta-analysis of randomized controlled trials (RCTs) of G-CSF as an adjunctive therapy to standard therapy versus standard therapy was performed. The endpoints were defined as (1) target-vessel restenosis, (2) cumulative cardiac events (CCEs) that were a combined endpoint of all-cause deaths, reinfarction, and target-vessel revascularization, and (3) the changes in left ventricular ejection fraction (LVEF) from baseline to follow-up. 320 patients were involved in 6 RCTs, of whom 160 were randomized to the G-CSF group and 160 to the control group. The follow-up period was 6.17 ± 3.49 months. There was no significant difference in the risk of target-vessel restenosis (P = 0.90) or CCEs (P = 0.59) between the two groups. When a pooled analysis of the changes in LVEF was performed with fixed-model effect, a significant heterogeneity was observed (P < 0.00001). The pooled analysis was thus conducted with random-model effect and did not show a significant improvement as compared to the control group (P = 0.34). A similar result was found in the sensitivity analysis based on five placebo-controlled trials involving 270 patients (P = 0.94). G-CSF as an adjunctive therapy to standard therapy for patients with AMI may be safe. However, there is not much supporting evidence that this treatment could further improve LVEF. Since there are relatively few RCTs that meet the inclusion criteria and are heterogeneous in design, further research is required.Keywords
This publication has 35 references indexed in Scilit:
- Feasibility and safety of granulocyte colony-stimulating factor treatment in patients with acute myocardial infarctionInternational Journal of Cardiology, 2007
- Intracoronary infusion of the mobilized peripheral blood stem cell by G-CSF is better than mobilization alone by G-CSF for improvement of cardiac function and remodeling: 2-Year follow-up results of the Myocardial Regeneration and Angiogenesis in Myocardial Infarction with G-CSF and Intra-Coronary Stem Cell Infusion (MAGIC Cell) 1 trialAmerican Heart Journal, 2007
- Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trialAmerican Heart Journal, 2006
- Safety of granulocyte-colony-stimulating factor in acute myocardial infarction (the Rigenera study)Heart, 2006
- Effects of GM-CSF on the stem cells mobilization and plasma C-reactive protein levels in patients with acute myocardial infarctionInternational Journal of Cardiology, 2006
- Postinfarct Cytokine Therapy Regenerates Cardiac Tissue and Improves Left Ventricular FunctionCirculation Research, 2006
- Macrophage Colony-Stimulating Factor Treatment After Myocardial Infarction Attenuates Left Ventricular Dysfunction by Accelerating Infarct RepairJournal of the American College of Cardiology, 2006
- Treatment with granulocyte colony–stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarctionAmerican Heart Journal, 2005
- Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart diseaseInternational Journal of Cardiology, 2005
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986